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a b s t r a c t
Headaches are one of the most common pain syndromes experienced by adult patients.
International Classiﬁcation of Headache Disorders identiﬁes about 300 different entities.
Primary headaches (migraine, tension-type headache, trigeminal autonomic cephalalgias,
other primary headaches) has the common occurrence. Although effective treatment of
these disorders is possible, it is inefﬁcient or poorly tolerated in some patients. Neuromo-
dulation methods, being element of multimodal treatment, provide an additional treatment
option in pharmacotherapy-refractory patients. Both invasive and non-invasive stimulation
methods are used. The non-invasive techniques is transcutaneous nerve stimulation using
Cefaly® device. In this study, Cefaly® was used as prevention treatment in patients with
pharmacotherapy-refractory headaches. This device is indicated for the prophylactic treat-
ment of episodic primary headaches. A total of 91-patients (30 without and 61 with tSNS)
were enrolled in the study, including 60-patients with migraine and 31-patients with other
primary headaches. Ten courses of non-invasive peripheral (supraorbitral/supratrochlear)
nerves stimulation were delivered to 57-patients; in the remaining 4 patients, the treatment
was abandoned due to poor tolerance. Patients were observed for 30 days after stimulation
treatment. Compared to the pre-treatment period, the reduction in the intensity of pain was
observed in both the migraine group and patients with other types of headaches; this
included the number of pain episodes being reduced by half, with simultaneous reduction in
average pain intensity and duration of individual pain episodes. The subjective assessment
of pain reduction was in the range of 40–47%. Based on our data we recommend tSNS as
useful tool in the prophylaxis of primary headaches, including migraine.
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Headaches are one of the most common pain syndromes
today. About 300 types of headaches were described; most of
these are rare conditions [1]. The most common are primary
headaches (migraine, tension-type headache, trigeminal
autonomic cephalalgias, other primary headaches). They
may be a serious health problem signiﬁcantly affecting the
daily functioning of patients [2,3]. Numerous randomized,
controlled studies were conducted to assess the most efﬁcient
and safe pharmacological treatment of headaches [1,2,4].
However, in many cases the treatment (either symptomatic,
prophylactic, pharmacological or non-pharmacological) does
not meet the patients' expectations due to non-satisfactory
efﬁcacy or adverse effects [2–6]. Ongoing research is pursued to
develop new treatment methods, both pharmacological and
non-pharmacological, to be applied in this group of patients.
Neurostimulation has been an established treatment method
for many years; recently, numerous articles have been
published on the use of neurostimulation techniques in
patients suffering from headaches [5,7–10]. Cefaly® transcu-
taneous nerve stimulation is one of the novel options in
peripheral stimulation and is indicated for the prophylactic
treatment of episodic migraine in patients 18 years of age or
older [12,14]. The method is used in both symptomatic and
prophylactic treatment of headaches. As demonstrated by
randomized, controlled studies, the method may be particu-
larly efﬁcient in prophylactic treatment of migraine and
tension type headaches [8,11,12]. The efﬁcacy of the treatment
of migraines by means of peripheral nerve stimulation is
currently the subject of extensive research [10–14].
2. Material and methods
2.1. Study objective
The objective of our study was to assess the effects of
prophylactic, non-invasive neurostimulation of the upper
branch of trigeminal nerve, i.e. supratrochlear and supraor-
bital nerves, using the Cefaly® device on the frequency,
intensity, and duration of headache episodes in patients with
migraine headaches and patients with other primary head-
aches (chronic daily and tension type headaches) compared to
the patients treated only with pharmacotherapy (control).
Every patient in study group was subjected to 10 cycles of
stimulation using the prophylactic low-frequency (60 Hz)
pulse program available in the device. The duration of active
stimulation was 20 min in all patients.
2.2. Material
A prospective study was conducted between January 2015 and
December 2016 in 91 headache-suffering patients. All the
patients enrolled to the study were treated with pharmacother-
apy according to valid recommendations of primary headaches
therapy. This therapy included prophylactic therapy (the most
common: antiepileptic, antidepressant, beta blockers), symp-
tomatic therapy: non-opioid analgesics (the most common:paracetamol, ketoprofen, ibuprofen, acetylosalicylic acid, meta-
mizol). Tryptans were used when was good tolerance to them
and were no contraindications to their use. The patients were
randomly selected to the 3 control groups (without tSNS) and 3
studied groups (with tSNS), but in both groups pharmacological
treatment was continued without any changes during the study
depending on individual needs. In the control group (without
tSNS treatment) the 30 patients kept their pain diaries where
they recorded every episode of headache along with its duration
and medications taken during observation period (similar to the
tSNS group). The 61 patients was rented tSNS Cefaly® devices
(CEFALY-Technology STX-Med in Herstal, Liege, Belgium). Prior
to qualiﬁcation for the tSNS (ca. 30. days) and during the follow-
up period, all enrolled patients kept their pain diaries where
they recorded every episode of headache along with its duration
and medications taken.
Study inclusion criteria for the patients enrolled to the
study:
- Age of 18–60 years.
- Migraine headache diagnosed on the basis of International
Headache Society diagnostic criteria for migraine with and
without aura [1].
- Other primary headaches (tension-type headache, trigemi-
nal autonomic cephalalgias, other primary headaches)
according to International Headache Society diagnostic
criteria for these disorders [1].
- Patient's consent to participate in the study.
- No contraindications to electrotherapy.
- Patients who had previously undergone other treatment
according to valid recommendations.
- No serious general disorders restricting the possibility of
treatment.
Study exclusion criteria:
- Incomplete diagnostics of headaches.
- Diagnostic criteria or migraine, tension, or chronic daily
headache not met.
- History of arrhythmias, pacemaker implantation, epilepsy or
other reasons precluding the use of electrotherapy.
- No previous treatment according to valid recommendations.
- Patient not giving consent for participation at the study and
kept pain diaries.
The study was approved by the Local Bioethics Committee.
Volunteers qualiﬁed for the study were informed of the study
objectives as well as the beneﬁts and possible adverse effects of
stimulation, and expressed their informed consent to partici-
pate in the study. Patients could discontinue their participation
at any time. Statistical analysis was provided only for the
patients who had unchanged drugs and their doses during
whole study. If it was necessary to change pharmacological
treatment or notes in the diary raised our doubts the patients
were excluded from the study. The statistical analysis was
provided blindly when we have collected data from patients. A
total of 91 patients (30 without tSNS and 61 with tSNS) were
enrolled in the study. The control group (with only pharmaco-
logical treatment), which mean the group without tSNS was
completed by 30 patients (20 patients with migraine headaches,
Fig. 1 – The number of 91 patients with headache in
individual age groups.
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patients suffering from migraine without aura, and 10 patients
with other primary headaches). The tSNS study was completed
by 57 patients (36 patients with migraine headaches, including
16 patients suffering from migraine without aura and 20
patients suffering from migraine with aura, and 21 patients
with other primary headaches); 4 patients with migraine
headaches discontinued the study due to poor toleration of
stimulation (inability to tolerate paresthesia, strong discomfort
experienced within the stimulated nerves during stimulation,
no willingness to continue stimulation).
2.3. Method
Transcutaneous nerve stimulation using the Cefaly® device is a
method of non-invasive electrotherapy employing the trans-
cutaneous electrostimulation principle. Appropriate electrodes
may be used for stimulation of supraorbital, supratrochlear or
occipital nerves. Electric pulses generated by the device
selectively stimulate the nerve ﬁbers. The treatment may be
delivered using either of 3 available modes: the treatment mode
used for migraine, tension type headaches and cluster head-
aches treatment employing high-frequency pulses (100 Hz), the
prophylactic mode used for preventing headaches between pain
episodes, employing low-frequency pulses (60 Hz) and relaxa-
tion mode used to deliver relaxation and relief in stress and
anxiety. The duration of stimulation session is 20 min in all
modes [14]. In our study, the prophylactic mode was used. The
device was programmed so that the intensity of pulses
increased gradually over the 20-min stimulation period.
Escalation of pulses could be stopped at any moment should
they become too painful for the patients. Patients could resign
from undergoing the treatment session at a particular day or to
discontinue their participation in the study. In the study, all
patients were subjected to stimulation of the upper branch of
the trigeminal nerve: supraorbital and supratrochlear nerves.
The study series consisted of 10 stimulation courses. Courses
were delivered to individual patients 2 or 3 times a week. Each
stimulation session lasted for 20 min. Numerical rating scale
(NRS) was used to assess pain before each treatment. The
sessions were not administered during headache episodes.
Patients were observed for any adverse effects during and after
the procedure. Stimulation could be discontinued at any time
should there be any need to do so. The efﬁcacy of treatment was
assessed 30 days after last stimulation procedure. The
assessment included the monthly number of episodes (days
with pain), duration of episodes (in hours), and pain intensity in
NRS during an episode. The results were compared to the
number, duration, and intensity of episodes as assessed before
the treatment. Subjective percentage improvement was also
assessed by the patients 30 days after stimulation treatment.
The results were compared to the appropriate control group.
2.4. Data analysis
The data are presented as mean  S.E.M. per six groups (three
control groups of patients: migraine with aura, n = 12; migraine
without aura, n = 8; other primary headaches, n = 10 and three
tSNS-stimulated groups of patients: migraine without aura,
n = 16; migraine with aura, n = 20; other primary headaches,n = 21). Inter-group differences were statistically evaluated by
ANOVA followed by Bonferroni's post hoc test. Signiﬁcance
was deﬁned as *p < 0.05, **p < 0.01 and ***p < 0.001 before vs.
after tSNS and as #p < 0.05, ##p < 0.01, ###p < 0.001 with vs.
without tSNS.
3. Results
3.1. Age and sex analysis of the patients suffering from
headaches
Fig. 1 presents the numbers of 91 patients in individual age
groups. The number of patients experiencing headaches
increases markedly above the age of 30. A strong drop is
observed after the age of 60. In general, the incidence of
migraine is reduced after the age of 60, particularly in post-
menopausal women receiving no estrogen replacement
therapy. Ten courses of non-invasive peripheral nerve
stimulation (supraorbitral and supratrochlear nerves) were
delivered to 57 patients; in the remaining 4 patients, the
treatment was abandoned due to poor tolerance.
Importantly, the mean age of patients in individual groups
was similar (45 years, Fig. 2A). Also non-signiﬁcant was the
mean duration of the disorder in years, as presented in Fig. 2B.
In all patients suffering from migraine, either with or without
aura, the duration of the disorder was 19 years while all
patients classiﬁed into the group of ‘‘other primary head-
aches’’ had suffered for the average period of 8 years.
The analysis of percentage populations of the patients
revealed that male patients comprised about 13% of the group
complaining of migraines without aura, 5% of the group
complaining of migraines with aura, and nearly one half (53%)
of the group complaining of other primary headaches (Fig. 3).
3.2. Frequency, duration and numeric rating scale scores
in patients with headaches
The study showed that the average monthly number of pain
days before the 10 courses of non-invasive peripheral nerves
Fig. 2 – (A) Mean age of the patients suffering from individual types of headaches in a group without (control) and with tSNS.
(B) Duration of the headache disorder (in years) patients suffering from individual types of headaches. Migraine without aura
(M/NA), migraine with aura (M/A) and other primary headaches (PH). Non-invasive transcutaneous Supraorbital
Neurostimulation (tSNS) using Cefaly® device (tSNS).
Fig. 3 – Percentage of female (F) and male (M) patients complaining of migraine without aura (M/NA), migraine with aura (M/A)
and other primary headaches (PH).
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migraine with and without aura, amounting to about 9 days
while being as high as 18 for other primary headaches.
Statistically signiﬁcant reduction in the frequency of the
headaches was observed following the treatment in all three
pain disorders (Fig. 4). In contrast, in all 3 groups of patients
without peripheral nerves stimulation we did not observed
such decrease of the frequency of the headaches.
The study showed that the average duration of pain
episode before the 10 courses of non-invasive peripheral
nerves stimulation (supraorbital and supratrochlear) was
similar for migraine with and without aura, amounting to
about 23–27 h while being shorter and lasting for 9–13 h. For
other primary headaches amounting to about 12 h while being
shorter and lasting for 7 h. Statistically signiﬁcant reduction in
the duration of pain was observed following the treatment in
all kind of headaches with tSNS (Fig. 5). In all 3 groups of
patients without peripheral nerves stimulation we did not
observed signiﬁcant reduction of the duration of pain.
The study revealed that the average NRS intensity of pain
as measured before the 10 courses of non-invasive peripheral
nerves stimulation (supraorbital and supratrochlear) was
similar for migraine with and without aura as well as forother headaches and amounted to about 7.8–8.8. A statistically
signiﬁcant reduction (36–37%) in the intensity of pain during
the pain episode was observed after the tSNS treatment in all
kind of headaches (Fig. 6). In contrast, in all three groups of
patients without peripheral nerves stimulation we did not
observed signiﬁcant decrease of the intensity of pain during
the pain episode during observation period.
3.3. Pain decrease in patients without and with tSNS
In all 3 groups of patients without peripheral nerves stimula-
tion we observed only slightly 11.5% and 25.6% decrease in
pain sensitivity as measured by NRS scale and subjective
improvement, respectively. The study revealed that patients
with low-intensity of pain (NRS 1–6) experienced lower
reduction of pain amounting to about 22% (data not shown on
the graph). Meanwhile, in patients who experienced stronger
pain (NRS 7–10) after the tSNS treatment, the pain reduction as
measured by NRS scale was similar and averaged to about 32–
34% in migraine with aura, migraine without aura, and other
primary headaches (Fig. 7A). Subjective improvement, i.e. the
symptom relief 30 days after stimulation as assessed by the
patients after the tSNS treatment using the percentage scale
Fig. 4 – The frequency of headache episodes (days/month) in
patients with strong pain (NRS 7–10) in individual pain
disorders at the beginning (B) and at the end (E) of the
examination in a group without (control) and with tSNS.
Inter-group differences were statistically evaluated by
ANOVA followed by Bonferroni's post hoc test. Significance
was defined as *p < 0.05, **p < 0.01 and ***p < 0.001 before
and at the end of study. Migraine without aura (M/NA),
migraine with aura (M/A) and other primary headaches
(PH). Non-invasive transcutaneous Supraorbital
Neurostimulation (tSNS) using Cefaly® device (tSNS).
Fig. 5 – The duration of pain episodes (hours) in patients
with strong pain (NRS 7–10) in individual pain disorders at
the beginning (B) and at the end (E) of the examination in a
group without (control) and with tSNS. Inter-group
differences were statistically evaluated by ANOVA followed
by Bonferroni's post hoc test. Significance was defined as
*p < 0.05, and ***p < 0.001 before and at the end of study.
Migraine without aura (M/NA), migraine with aura (M/A)
and other primary headaches (PH). Non-invasive
transcutaneous Supraorbital Neurostimulation (tSNS)
using Cefaly® device (tSNS).
Fig. 6 – Numeric Rating Scale scores in patients with strong
pain (NRS 7–10) in individual pain disorders at the
beginning (B) and at the end (E) of the examination in a
group without (control) and with tSNS. Inter-group
differences were statistically evaluated by ANOVA followed
by Bonferroni's post hoc test. Significance was defined as
***p < 0.001 before and at the end of study. Migraine
without aura (M/NA), migraine with aura (M/A) and other
primary headaches (PH). Non-invasive transcutaneous
Supraorbital Neurostimulation (tSNS) using Cefaly®
device (tSNS).
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47% (Fig. 7B).
4. Discussion
Although effective treatment of primary headaches is possi-
ble, the proposed pharmacological treatment is inefﬁcient or
poorly tolerated in some patients. The available methods for
the treatment of migraine headaches are not always satisfac-
tory for patients in terms of symptom relief. It is estimated that
chronic headaches experienced every day or nearly every day
to a degree reducing individual's abilities may affect about 1.4–
2.2% of the overall population. Reduced abilities may result
from insufﬁcient efﬁcacy of the treatment or from the adverse
effects thereof [5]. The intensity of migraine varied. As many as
25% of patients experience more than 4 severe episodes per
month, 48% experience 1–4 severe episodes per month, and
38% experience 1 severe episode per month. Most patients in
the study group experienced more than 4 severe pain episodes
per month. Symptomatic treatment fails in 1 out of 4 migraine
patients and it may cause adverse effects [15,16]. In addition,
contraindications to tryptans treatment may exist. About 3%
of patients with chronic primary headaches are refractory to
prophylactic treatment [13,17,18]. The inefﬁcacy of treatment
may signiﬁcantly affect the quality of life of patients,
particularly those with frequent pain episodes. The varied
frequency of pain episodes, signiﬁcant intensity of pain, and
unsatisfactory efﬁcacy of the treatment in the study group
triggered the search for novel treatment options.
Fig. 7 – Pain decrease in patients with high-intensity pain (NRS 7–10) in a group without (control) and with tSNS. (A) NRS score;
(B) subjective % pain decrease as reported by patients. Inter-group differences were statistically evaluated by ANOVA
followed by Bonferroni's post hoc test. Significance was defined as #p < 0.05, ##p < 0.01, ###p < 0.001 with vs. without tSNS.
Migraine without aura (M/NA), migraine with aura (M/A) and other primary headaches (PH). Non-invasive transcutaneous
Supraorbital Neurostimulation (tSNS) using Cefaly® device (tSNS).
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ment method for many years, only recently it has become a
subject of particular interest, mostly due to the emergence of
new abilities allowing for planned, precise modulation of
nociceptive processes. Neuromodulation techniques used in
the treatment of headaches may be categorized into invasive
methods including peripheral methods such as stimulation of
peripheral nerves, and central methods such as motor cortex,
spinal cord, deep brain, or sphenopalatine ganglion stimula-
tion. Non-invasive techniques of headache treatment include
peripheral methods such as transcutaneous electrostimulation
and central methods such as transcranial magnetic stimula-
tion, or transcranial direct current stimulation [8,9,11–13,19].
The main principle of these treatment methods includes
modulation of nervous system structures that are directly or
indirectly involved in nociception starting from the stimulus
generation and ending on its cerebral perception. The methods
include direct modulation of brain structures involved in the
development of pain episodes (deep hypothalamic stimulation
in cluster headaches), modulation of inhibitory antinocicep-
tive systems (stimulation of occipital nerves), modulation of
cortical excitability transcranial magnetic stimulation or
transcranial direct current stimulation) [7–9].
In case of transcutaneous electrostimulation of nerves, the
therapeutic effect is achieved by electrical stimulation of skin
within the painful region to interact with the sensory nerves.
The method involves the use of currents of varied intensity
and frequency. In principle, the mechanism of action is
explained by transcutaneous stimulation leading to inhibited
nociception by means of interacting with nerve ﬁbers within
the area subjected to stimulation treatment. The use of high
frequencies of 80–200 pulses per second and low amplitudes
results in excitation of thick Ab ﬁbers (muscle efferent ﬁbers)
and segmental analgesia. The use of lower frequencies
(conventional TENS) affects thin Ad ﬁbers as well and leads
to suprasegmental analgesia [7,20].
Stimulation of peripheral nerves using implanted electro-
des brought about promising outcomes in patients withmigraine and cluster headaches [20]. Good therapeutic effect
was achieved in about 50% of patients [20]. The electrodes were
implanted in the vicinity of supraorbital nerves (migraine
headaches) or occipital nerves (cluster headaches) [19–21].
However, due to the need of subcutaneous placement of
electrodes, the method is recommended only in patients with
particularly strong pain. As shown by our studies, non-
invasive methods employing electrodes being placed on the
skin, is an alternative approach that may be used in a larger
number of patients. Randomized studies demonstrated the
efﬁcacy of the stimulation of supraorbital nerves in the
prevention of migraine headaches [11–13].
Neuromodulation techniques are an additional option in
the currently proposed multimodal model of chronic pain
treatment [22]. They may be particularly useful in patients in
whom the pharmacological treatment compliant with recom-
mendations was either inefﬁcient or led to unacceptable
adverse effects. Neuromodulation techniques may also be
used in patients in whom the applicability of pharmacological
treatment is reduces due to coexisting diseases. Particularly
attractive alternative is proposed by non-invasive techniques
that may be used in primary headache patients.
An interesting, non-invasive solution for patients with
primary headaches may consist of non-invasive stimulation of
peripheral nerves using tSNS with the Cefaly® device. The
method is based on the principle of transcutaneous electro-
stimulation. A self-adhesive stimulation electrode is placed in
the frontal region and stimulation affects the upper branches
of the trigeminal nerve, i.e. supraorbital and supratrochlear
nerves [14]. Three operation modes (treatment mode, prophy-
lactic mode and relaxation mode) may be used for the
management or prevention of pain. The treatment mode to
be used during pain episodes involves generation of very high-
frequency pulses that stimulate the sensory sensitivity of Ab
nerve ﬁbers. Excitation of these ﬁbers blocks the nociceptive
information within the central nervous system. The treatment
mode is efﬁcient and permits the reduction of pain during the
pain episode; however, it may be used only in clinical setting
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reduces tension and stress which may be helpful in preventing
the recurrence of headaches.
As shown by our studies and conﬁrmed by literature
reports, prophylactic mode may be safely used at home; in our
opinion, this makes this treatment option particularly attrac-
tive. The prophylactic mode consists in generation of lower-
frequency pulses (60 Hz) that stimulate the Ad nociceptive
ﬁbers. Appropriate frequency of stimulation of these ﬁbers
markedly increases endorphin production. Endorphin secre-
tion leads to overall relaxation and good feeling. In addition,
endorphins regulate serotoninergic structures within the
central nervous system, being impaired in patients suffering
from migraine [7,19]. In the prophylactic mode, the device-
driven stimulation is delivered outside strong pain episodes.
The efﬁcacy of the method was demonstrated in a randomized
controlled trial conducted in 5 headache treatment centers in
Belgium [11]. The results of this study indicate that stimulation
of supraorbital nerves brought about signiﬁcant improvement
in patients receiving active treatment as compared to placebo,
consisting in reduced number of days with pain symptoms,
and consumption of analgesics being reduced by 75% within
the follow-up period of 3 months [11].
In our study, the Cefaly® device was used in patients with
migraine headaches presenting both with aura and without
aura in whom the symptoms occurred bilaterally, unilaterally,
or within the occipital region. A majority of migraine patients
was female, which was consistent with observations provided
by other authors [1,16,22]; in the remaining types of primary
headaches, the percentages of male and female patients were
similar, which was also consistent with the literature reports
[2,16,22].
In our patients, the average duration of pain episode before
the peripheral stimulation was similar for migraine with and
without aura, amounting to about 23–27 h, which was in line
with literature values [2,16]. Patients with other primary
headaches experienced shorter episodes of about 9–13 h. The
average pain intensity as measured using NRS was similar and
amounted to about 7.8–8.8, which was in line with previous
reports in which the pain associated with primary headaches
was usually assessed as NRS 7–9 [16,23]. In our study, the
prophylactic mode of stimulation was used and the treatment
was delivered in pain clinic between the headache episodes. No
procedures were performed in patients who experienced strong
pain on the day of scheduled stimulation. In our study, all
patients were subjected to supraorbital nerve stimulation. The
number of stimulation courses delivered as part of the series
was 10 regardless of the type of headache disorder. A total of 61
patients were enrolled in the group with tSNS. The study was
completed by 57 patients; 4 patients discontinued the treat-
ment due to the discomfort associated with stimulation: they
could not tolerate the sensations within the stimulated nerves
during the stimulation. This was also reported in previous
studies by Magis et al. in 2013, with the intolerance to
paresthesia during stimulation comprising the most common
adverse effect accounting for 46% of all adverse effects observed
in the study [12]. Similar to our observations, patients who
could not tolerate paresthesias discontinued their participation
in the study [12]. Otherwise, slight skin irritation at electrode
application site, persisting for up to 30 min, was observed in 4patients participating in our study. We could not observe
allergic reactions or other adverse effects (sleepiness during the
session, headache after a session, vomiting after a session,
nausea and vertigo during sessions, migraine feeling during
sessions) reported in 2013 by Magis et al. [20].
We observed a signiﬁcant reduction in the average monthly
number of pain episodes (days with pain) in our study group.
We were able to demonstrate that in patients with pain of high
intensity, i.e. NRS grade 7–10, the average pain relief was in the
range of ca. 32–34%. Our study result indicates a measurable
reduction in pain as assessed by NRS compared to the baseline
conditions. Although the intensity of pain is a measurable
parameter which can assessed treatment efﬁcacy, no such
assessments were conducted in the remaining studies [12].
The result is considered good as prophylactic pharmacolog-
ical treatment fails in 1 in 2 patients with most patients
experiencing unacceptable adverse effects. Blumenfeld et al.
(2013) reported that as little as 28.3% of patients complied with
the proposed pharmacological prophylactic treatment. The
reasons for treatment discontinuation included lack of efﬁcacy
and side effects in an equal proportion. Symptomatic treatment
during the pain episodes in ineffective in 1 in 4 patients; in
addition, it may lead to adverse effects or be precluded due to
certain contraindications [6,18]. Our control group during
period of observation similar to the tSNS group conﬁrmed
difﬁculties and lack of full effectiveness of individually
matched pharmacotherapy. In light of these data, the proposed
non-invasive prophylactic treatment is a very useful method.
We have collected our data for a long period of time (24
months), since it was necessary that patients did not change
their pharmacological treatment during whole study and diary
notes had to be reliable. Moreover, it was impossible to provide
the tSNS blindly, because patients have felt stimulation.
However, the statistical analysis was provided blindly at the
end of the study.
Notably, the proposed method was used with 47 and 40%
efﬁcacy, in migraine and other primary headache patients,
respectively. The average disease duration of 19 years for
migraine patients and 9 for other headache in whom numerous
therapeutic options had been previously used. The patient
reported treatment satisfaction in the studies conducted in
2013 by Schoenen et al. and Magis et al. was 61.7% and 58.8%,
respectively. However, the authors described the patients who
has different numbers of tSNS sessions, some of them even
more then 20. The results obtain in our studies show that even
after 10 tSNS sessions the average percentage pain relief was
40–47% and the patients were satisﬁed with the proposed
treatment.
5. Conclusions
Our study give evidence that following the prophylactic
program of supraorbital and supratrochlear nerves stimula-
tion, the average monthly number of pain episodes was
reduced by half compared to the pre-treatment period and to
the appropriate control groups. In patients who experienced
strong pain (NRS 7–10) with only pharmacological treatment
the pain reduction as measured by NRS scale was averaged to
about 10–12.5%. Meanwhile, in patients with pharmacological
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scale was averaged to about 32.7; 32.8 and 34% in migraine
with aura, migraine without aura, and other primary head-
aches, respectively. We demonstrate for the ﬁrst time the
similar effectiveness of Cefaly in patients with this different
types of primary headaches. Subjective improvement
assessed by the patients after the tSNS treatment using the
percentage scale was averaged about 40–47%, in contrast in the
control group was averaged to about 22.5–28.8%. In a similar
manner, decrease was observed in the average intensity and
duration of pain during the episode compared to the pre-
treatment period. Based on our and literature data we
recommend tSNS as useful tool in the prophylaxis of different
types of primary headaches, including migraine. It is a non-
invasive method that is safe for the patients and associated
with a low risk of adverse effects and well tolerant.
Conﬂict of interests
None declared.
Acknowledgment and ﬁnancial support
Supported by statutory funds of the Department of Pain
Research and Treatment, Chair of Anesthesiology and Inten-
sive Therapy, Jagiellonian University Medical College, Krakow,
Poland and by statutory funds of the Institute of Pharmacolo-
gy, Polish Academy of Sciences.
Ethics
The work described in this article has been carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans; Uniform Requirements for manuscripts submit-
ted to Biomedical journals.
r e f e r e n c e s
[1] Headache Classiﬁcation Committee of the International
Headache Society. The International Classiﬁcation of
Headache Disorders: 3rd edition (beta version) International
Headache Society 2013. Cephalalgia 2013;33(9):629–80.
[2] Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML,
Turkel CC, et al. Chronic migraine prevalence, disability,
and socio demographic factors: results from the American
Migraine Prevalence and Prevention Study. Headache
2012;52(10):1456–70.
[3] Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB,
Goadsby PJ, et al. Cost of healthcare for patients with
migraine in ﬁve European countries: results from the
International Burden of Migraine Study (IBMS). J Headache
Pain 2012;13(5):361–78.
[4] Goadsby PJ, Sprenger T. Current practice and future
directions in the prevention and acute management of
migraine. Lancet Neurol 2010;9:285–98.
[5] Berg J, Stovner LJ. Cost of migraine and other headaches in
Europe. Eur J Neurol 2005;12(Suppl 1):59–62.[6] Fenstermacher N, Levin M, Ward T. Pharmacological
prevention of migraine. BMJ 2011;18. 342:d583.
[7] Jenkins B, Tepper SJ. Neurostimulation for primary
headache disorders, part 1: pathophysiology and anatomy,
history of neuromodulation in headache treatment, and
review of peripheral neuromodulation in primary
headaches. Headache 2011;51(8):1254–66.
[8] Jürgens T. Neuromodulation in primary headaches. Pain
Clinical Updates International Association for the Study of
Pain (IASP) 2012;20(5):1–7.
[9] Rokyta R, Fricová J. Neurostimulation methods in the
treatment of chronic pain. Physiol Res 2012;61(Suppl. 2):
23–31.
[10] Clarke BM, Upton AR, Kamath MV, Al Habri T, Castellanos
CM. Transcranial magnetic stimulation for migraine:
clinical effects. J Headache Pain 2006;7(5):341–6.
[11] Schoenen J, Vandersmissen B, Jeangette S, Herroelen L,
Vandenheede M, Gérard P, et al. Migraine prevention with a
supraorbital transcutaneous stimulator. A randomized
controlled trial. Neurology 2013;80(8):697–704.
[12] Magis D, Sava S, Sasso d'Elia TS, Baschi R, Schoenen J.
Safety and patients' satisfaction of transcutaneous
Supraorbital NeuroStimulation (tSNS) with the Cefaly®
device in headache treatment: a survey of 2,313 headache
sufferers in the general population. J Headache Pain 2013;1.
14:95.
[13] Przeklasa-Muszynska A, Skrzypiec K, Kocot-Kępska M,
Dobrogowski J. Neuromodulation in headache treatment –
clinical use of peripheral nerves stimulation for patients
with migraine headache. Ból 2014;15(2):31–8.
[14] Cefaly Supraorbital Transcutaneous Nerve Stimulation
Copyright © 2016 Cefaly Technology. http://www.
cefalytechnology.com/en/products
[15] Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life
impairment, disability and economic burden associated
with chronic daily headache, focusing on chronic migraine
with or without medication overuse: a systematic review.
Cephalalgia 2011;31(7):837–50.
[16] Lipton RB, Silberstein SD. Episodic and chronic migraine
headache: breaking down barriers to optimal treatment and
prevention. Headache 2015;55(Suppl. 2):103–22.
[17] Silberstein SD. Preventive migraine treatment. Neurol Clin
2009;27(2):429–43.
[18] Gallagher RM, Kunkel R. Migraine medication attributes
important for patient compliance: concerns about side
effects may delay treatment. Headache 2003;43(1):36–43.
[19] Jenkins B, Tepper SJ. Neurostimulation for primary
headache disorders: part 2, review of central
neurostimulators for primary headache, overall therapeutic
efﬁcacy, safety, cost, patient selection, and future research
in headache neuromodulation. Headache 2011;51(9):
1408–18.
[20] Magis D, Schoenen J. Advances and challenges in
neurostimulation for headaches. Lancet Neurol 2012;11
(8):708–19.
[21] Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV,
Sharan A, et al. Safety and efﬁcacy of peripheral nerve
stimulation of the occipital nerves for the management of
chronic migraine: results from a randomized, multicenter,
doubleblinded, controlled study. Cephalalgia 2012;32
(16):1165–79.
[22] Tfelt-Hansen P. Headache. In: Stannard CF, Kalso E,
Ballantyne J, editors. Evidence-based chronic pain
management, vol. 22. Wiley-Blackwell BMJ/Books; 2010. p.
279–90.
[23] Sharav Y, Katsarova Z, Benoliel R. Migraine and possible
facial variants: neurovascular orofacial pain. In: Sharav Y,
Benoliel F, editors. Orofacial pain and headache, vol. 9.
Elsevier Health Sciences; 2008. p. 319–63.
